Transitional Cell Carcinoma of the Urothelial Tract

Transitional Cell Carcinoma of the Urothelial Tract

Transitional cell carcinoma of the urothelial tract, also known as urothelial tract carcinoma, is an aggressive form of cancer that affects the cells of the urinary tract. The urothelial tract contains cells called urothelial cells, which line the bladder, ureter, and other parts of the urinary tract system. When these cells become cancerous, they can spread to other parts of the body, such as the kidneys, prostate, and lungs. Urothelial carcinoma is the most common type of bladder cancer, accounting for 91% of all urinary cancer cases in the United States.

Urothelial carcinoma has several risk factors, which include smoking, exposure to certain chemicals, and advanced age. It is more common in men than women and is most likely to develop in people over the age of 65. People who have had bladder or urinary tract infections in the past, African Americans, and those with a family history of the disease are also at an increased risk of developing urothelial carcinoma.

When symptoms of urothelial carcinoma do occur, they may include:

  • Blood in the urine
  • Pain or burning while urinating
  • Frequent urination
  • Difficulty urinating
  • Lower back pain
  • Abdominal pain

If left untreated, urothelial carcinoma can spread to other organs and bones. Depending on the size and stage of the cancer, the patient may require radiation therapy, chemotherapy, or surgery to remove the cancerous cells. Early detection is key in treating urothelial carcinoma, as it is more difficult to treat if it has spread outside the bladder. Regular screenings, such as bladder cytology tests, are important to detect this form of cancer at an early stage.